
CLAIMS

We claim:

1. A compound of formula (II-A):



(II-A),

or a pharmaceutically acceptable salt thereof,

wherein:

R^1 is C_1-C_4 alkyl or halo;

R^2 is 5-6 membered heteroaryl, where said 5-6 membered heteroaryl is optionally substituted by 1 to 3 R^{32};

R^3 is H;

R^4 is selected from the group consisting of H, and halo;

m is 0 and R^5 is absent

each R^{32} is independently selected from the group consisting of -Cl, -F, -OH, $-CH_3$, $-CH_2CH_3$, $-CF_3$, $-CH_2OH$, $-CH_2OCH_3$, $-OCH_3$, $-OC_2H_5$, $-OCF_3$, -CN, $-C(O)NH_2$, $-C(O)NHCH_3$, $-C(O)N(CH_3)_2$, $-NHC(O)CH_3$, $-NH_2$, $-NHCH_3$, $-N(CH_3)_2$, cyclopropyl, 4-6 membered heterocyclyl, phenyl, and 5-6 membered heteroaryl, where said 4-6 membered heterocyclyl, phenyl, and 5-6 membered heteroaryl is optionally substituted by 1 to 3 halo, C1-C4 alkyl or C1-C4 alkoxy, which are independently selected;

X is C_1-C_4 alkyl;

Z is C_1-C_4 alkyl; and

Y is H.

2. The compound or salt of claim 1, wherein R^1 is Cl.

3. The compound or salt of claim 1, wherein R^2 is 5-6 membered heteroaryl selected from the group consisting of pyrazolyl, isoxazolyl or triazolyl, each of which is optionally substituted by 1, 2, or 3 R^{32}.

4. The compound or salt of claim 3, wherein each R^{32} is selected from the group consisting of $-CH_3$ and $-CH_2CH_3$.

5. The compound or salt of claim 1, wherein R^4 is halo.

6. The compound or salt of claim 5, wherein R^4 is Cl or Br.

7. A compound of claim 1 which is 5-bromo-8-chloro-2-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-(1,4-dimethyl-1*H*-1,2,3-triazol-5-yl)-3,4-dihydroisoquinolin-1(2*H*)-one, or a pharmaceutically acceptable salt thereof.

8. A compound of claim 1 which is 5,8-dichloro-7-(3,5-dimethyl-1,2-oxazol-4-yl)-2-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-3-4-dihydroisoquinolin-1(2*H*)-one, or a pharmaceutically acceptable salt thereof.

9. A compound of claim 1 which is 5-bromo-8-chloro-2-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-(1,4-dimethyl-1*H*-1,2,3-triazol-5-yl)-3,4-dihydroisoquinolin-1(2*H*)-one.

10. A compound of claim 1 which is 5,8-dichloro-7-(3,5-dimethyl-1,2-oxazol-4-yl)-2-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-3-4-dihydroisoquinolin-1(2*H*)-one.

11. A pharmaceutical composition comprising a compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

12. Use of a therapeutically effective amount of a compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, for the treatment of abnormal cell growth.

13. The use of claim 12, wherein the abnormal cell growth is cancer.

14. Use of a compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, and an anti-cancer agent, for the treatment of abnormal cell growth, wherein the compound, or pharmaceutically acceptable salt thereof, is adapted for administration sequentially or simultaneously with the anti-cancer agent.

15. Use of a therapeutically effective amount of a compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of abnormal cell growth.

16. The use of claim 15, wherein the abnormal cell growth is cancer.

17. Use of a compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, and an anti-cancer agent, in the manufacture of a medicament for the treatment of abnormal cell growth, wherein the compound, or pharmaceutically acceptable salt thereof, is adapted for administration sequentially or simultaneously with the anti-cancer agent.

18. A combination of a compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, and an anti-cancer agent.